Pharma BD Deal Intelligence
J&J bought Animas for $518M in 2006 to enter insulin pumps, then shut the unit down entirely in October 2017—laying off 297 employees and pushing roughly 90,000 patients to rival Medtronic. J&J held just 13% U.S. pump share versus Medtronic's 66% at the time of exit.
J&J bought its way into insulin pumps in 2006 and completely exited the business in 2017 — an 11-year, ~$518M dead end
Full analysis, sources & comparables →Animas 8-K disclosing the definitive merger agreement with Johnson & Johnson, $24.50 per share in cash, with the transaction expected to close in the first…
Coverage frames the deal as J&J's LifeScan entering the fast-growing insulin delivery pump market, a strategic complement to its blood-glucose monitoring…
J&J shuts down Animas insulin pump operations in US and Canada, transferring patients to Medtronic — a retrospective indictment of the original…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
J&J announces $518M acquisition of insulin pump maker Animas. Diabetes device deal. Closed Feb 17, 2006.
J&J bought its way into insulin pumps in 2006 and completely exited the business in 2017 — an 11-year, ~$518M dead end
Assessment window: 15yr post-close.
Type 1 diabetes is an autoimmune disease in which the pancreas produces little or no insulin, requiring lifelong insulin replacement. Insulin pumps deliver continuous subcutaneous insulin and improved glycemic control versus multiple daily injections, particularly for pediatric and adolescent patients.
In 2005, the US insulin pump market was concentrated around Medtronic MiniMed (clear category leader following its acquisition of MiniMed in 2001), Animas, Deltec Cozmo (Smiths Medical), and Insulet's first-generation OmniPod tubeless system. Animas held a strong number-two position with the IR 2020 pump and was developing the OneTouch Ping (launched 2008), which integrated J&J's LifeScan glucose meter with bolus communication. J&J framed the deal as combining LifeScan's glucose monitoring leadership with insulin delivery to deliver a more integrated diabetes management offering. The acquisition gave J&J a full-stack T1D platform, but the company struggled against Medtronic's closed-loop progression (Paradigm series, then 670G hybrid closed-loop in 2016) and Tandem's t:slim touchscreen platform. J&J ultimately exited the insulin pump business in October 2017, transferring patients to Medtronic. In hindsight, the deal is widely cited as a strategic device acquisition that failed to keep pace with software-driven automated insulin delivery innovation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Animas Corporation (this deal) | 2005 | $518M | 23 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2005 deals · Johnson & Johnson deals